News
Novavax’s COVID-19 vaccine ‘highly’ effective against UK variant
Novavax has announced that its COVID-19 vaccine NVX-CoV2373 has a final efficacy of 96.3% against mild, moderate and severe disease caused by the original COVID-19 strain in its UK-based Phase III trial.